The Roles of EXO1 and RPA1 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Table 4

Stratification analyses of association between polymorphisms and PFS or OS in lung cancer patients.

PFS/OS	Polymorphism	Genotype	Subgroup	Additive		Dominant		Recessive
				OR (95% CI)		OR (95% CI)		OR (95% CI)
PFS	rs17292622	RPA1	TNM2	1.56 (0.98-2.48)	0.060	1.89 (1.06-3.38)	0.032	1.34 (0.49-3.67)	0.563
OS	rs2228006	PMS2	≤60	0.31 (0.11-0.87)	0.027	0.31 (0.11-0.87)	0.027
	rs1062372	PMS2	LUAD	0.49 (0.20-1.20)	0.121	0.58 (0.18-1.81)	0.347	0.16 (0.03-0.95)	0.043

Additive model: comparison between minor allele subjects and major allele subjects. Dominant model: comparison between minor allele carriers and major homozygous subjects. Recessive model: comparison between major allele carriers and minor homozygous subjects. OR: odds ratio; CI: confidence interval. .